ResMedMEX:RMD 99 Piotroski F-Score is 7 as of Jun. 24, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 805 Medical Devices & Instruments companies, ResMed ranks better than 92.42% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ResMed has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for ResMed's Piotroski F-Score or its related term are showing as below:
MEX:RMD'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 9
Current: 7
During the past 13 years, the highest Piotroski F-Score of ResMed was 9. The lowest was 4. And the median was 6.
ResMed (MEX:RMD) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
ResMed Piotroski F-Score Related Terms
ResMed Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for ResMed's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where ResMed's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 7149.541 + 6393.614 + 7068.912 + 7190.215 = MXN27,802 Mil. Cash Flow from Operations was 10144.533 + 8389.188 + 6117.347 + 9992.496 = MXN34,644 Mil. Revenue was 25381.63 + 24500.183 + 25618.654 + 25812.115 = MXN101,313 Mil. Gross Profit was 15441.224 + 15057.286 + 15822.041 + 16066.757 = MXN62,387 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(154803.558 + 153917.243 + 152410.071 + 153109.129 + 158404.376) / 5 = MXN154528.8754 Mil. Total Assets at the begining of this year (Mar25) was MXN154,804 Mil. Long-Term Debt & Capital Lease Obligation was MXN9,990 Mil. Total Current Assets was MXN73,286 Mil. Total Current Liabilities was MXN24,366 Mil.
Net Income was 5353.794 + 6130.673 + 7187.333 + 7468.082 = MXN26,140 Mil.
Revenue was 22409.058 + 24110.95 + 26738.864 + 26426.593 = MXN99,685 Mil. Gross Profit was 13108.528 + 14122.257 + 15668.366 + 15679.349 = MXN58,579 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(113096.209 + 125902.966 + 142211.558 + 148937.519 + 154803.558) / 5 = MXN136990.362 Mil. Total Assets at the begining of last year (Mar24) was MXN113,096 Mil. Long-Term Debt & Capital Lease Obligation was MXN16,389 Mil. Total Current Assets was MXN65,638 Mil. Total Current Liabilities was MXN19,241 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
ResMed's current Net Income (TTM) was 27,802.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
ResMed's current ratio of this year was 3.00772044. ResMed's current ratio of last year was 3.41134023.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
ResMed's number of shares in issue this year was 145.723. ResMed's number of shares in issue last year was 147.22.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
ResMed's gross margin of this year was 0.61579033. ResMed's gross margin of last year was 0.58763331.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
ResMed's asset turnover of this year was 0.654459. ResMed's asset turnover of last year was 0.88142181.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
0
+
1
+
1
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ResMed has an F-score of 6 indicating the company's financial situation is typical for a stable company.
ResMed (MEX:RMD) has a Piotroski F-Score of 7 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ResMed and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, ResMed's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, ResMed ranks #61 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 7.6%.
Is ResMed's Piotroski F-Score too high?
ResMed's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. ResMed's value of 7 is 40% above this industry median. Based on the distribution chart, ResMed ranks #61 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Piotroski F-Score compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #61 out of 805 companies for Piotroski F-Score. This places ResMed in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. ResMed's value of 7 is 40% above this benchmark. Historically, ResMed's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Medical Devices & Instruments industry median of 5.00. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Piotroski F-Score is 7 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for MEX:RMD:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
Industry Position: 40% above the Medical Devices & Instruments median (#61 of 805)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
